La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Natera Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Natera sono diminuiti a un tasso medio annuo di -23.1%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 31%.

Informazioni chiave

-23.1%

Tasso di crescita degli utili

-14.9%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	31.0%
Rendimento del capitale proprio	-34.9%
Margine netto	-21.5%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Jul 05

Natera: Overdue For A Breather

Jun 03

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

May 12

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Aug 07

Health Check: How Prudently Does Natera (NASDAQ:NTRA) Use Debt?

May 16

Natera, Inc.'s (NASDAQ:NTRA) Low P/S No Reason For Excitement

Apr 18

Ripartizione dei ricavi e delle spese

Come Natera guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGS:NTRA Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Jun 24	1,361	-292	708	338
31 Mar 24	1,209	-365	663	327
31 Dec 23	1,083	-435	618	321
30 Sep 23	989	-499	601	326
30 Jun 23	931	-512	594	314
31 Mar 23	868	-546	591	318
31 Dec 22	820	-548	589	316
30 Sep 22	776	-546	592	300
30 Jun 22	723	-576	572	333
31 Mar 22	667	-546	550	304
31 Dec 21	625	-472	511	264
30 Sep 21	565	-408	453	231
30 Jun 21	505	-315	402	157
31 Mar 21	449	-258	346	122
31 Dec 20	391	-230	304	100
30 Sep 20	362	-189	272	77
30 Jun 20	342	-153	251	65
31 Mar 20	330	-126	226	58
31 Dec 19	302	-125	204	51
30 Sep 19	286	-121	189	49
30 Jun 19	273	-128	170	49
31 Mar 19	262	-129	161	48
31 Dec 18	258	-128	155	51
30 Sep 18	243	-144	163	50
30 Jun 18	233	-142	159	50
31 Mar 18	223	-137	156	50
31 Dec 17	210	-138	155	50
30 Sep 17	207	-128	144	49
30 Jun 17	205	-126	144	47
31 Mar 17	205	-121	143	46
31 Dec 16	213	-100	136	42
30 Sep 16	221	-81	129	38
30 Jun 16	212	-72	122	34
31 Mar 16	205	-69	117	31
31 Dec 15	190	-70	110	28
30 Sep 15	187	-46	98	24
30 Jun 15	189	-28	86	21
31 Mar 15	179	-6	72	19
31 Dec 14	159	-5	63	17
30 Sep 14	133	-11	55	16
31 Mar 14	78	-29	40	13
31 Dec 13	55	-37	32	12

Guadagni di qualità: NTRA al momento non è redditizia.

Margine di profitto in crescita: NTRA al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: NTRA non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 23.1% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di NTRA nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: NTRA non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 0.5% ).

Rendimento del capitale proprio

ROE elevato: NTRA ha un Return on Equity negativo ( -34.92% ), in quanto al momento non è redditizio.

Natera Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023)

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Recent updates

Consensus estimates of losses per share improve by 20%

Forecast to breakeven in 2026

Co-Founder & Executive Chairman exercised options to buy US$22m worth of stock.

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

Natera, Inc. to Report Q2, 2024 Results on Aug 08, 2024

CEO & Director notifies of intention to sell stock

Does Natera (NASDAQ:NTRA) Have A Healthy Balance Sheet?

Natera, Inc. Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer

CEO & Director notifies of intention to sell stock

Natera, Inc. Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients

Natera: Overdue For A Breather

New minor risk - Insider selling

Secretary & Chief Legal Officer notifies of intention to sell stock

Natera, Inc. (NASDAQ:NTRA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$119

Price target increased by 9.0% to US$113

Natera, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.56 loss per share (vs US$1.23 loss in 1Q 2023)

Natera, Inc. to Report Q1, 2024 Results on May 09, 2024

Natera, Inc., Annual General Meeting, Jun 12, 2024

CEO & Director notifies of intention to sell stock

Now 20% undervalued

Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (Modern) A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer

Is There An Opportunity With Natera, Inc.'s (NASDAQ:NTRA) 41% Undervaluation?

Natera: Capitalizing On The Positive Momentum Of Personalized Medicine

Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™? in Stage II Colorectal Cancer

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 11%

Is Natera (NASDAQ:NTRA) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$86.94

Natera, Inc. Provides Earnings Guidance for the Year 2024

Natera, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Natera, Inc. Announces New Study Demonstrates Signatera's Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Provides Update on Ravgen Trial

Natera, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2023

Natera Announces New Study Highlighting the Benefits of Signatera's Unique Method of Quantifying ctDNA

Estimating The Fair Value Of Natera, Inc. (NASDAQ:NTRA)

Natera, Inc. Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023

Natera, Inc. Raises Revenue Guidance for the Full Year 2023

Is Natera (NASDAQ:NTRA) A Risky Investment?

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Natera, Inc. Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Natera's RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight in Chronic Kidney Disease

Co-Founder & Director notifies of intention to sell stock

Natera, Inc. Announces Updated Data from the Galaxy Arm of the Circulate-Japan Trial

Natera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Natera, Inc. to Present New Signatera MRD Data At ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study

Natera, Inc. Announces New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early

Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera

Natera, Inc. Announces Senior Leadership Appointments

Natera, Inc. Announces Expanded I-Spy 2 Collaboration to Evaluate Signatera™? for Breast Cancer Patients in the Neoadjuvant Setting

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Natera, Inc. has completed a Follow-on Equity Offering in the amount of $250.25 million.

Co-Founder & Director notifies of intention to sell stock

Natera's Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

Natera, Inc. (NASDAQ:NTRA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Natera, Inc. Revises Earnings Guidance for the Year 2023

Natera Announces Completion of Enrollment to the Randomized, Phase III Altair Trial of Signatera in Colorectal Cancer

Co-Founder & Director notifies of intention to sell stock

United States District Court for the District of Delaware Issues Favorable Ruling for Natera, Inc. in False Advertising Trial Against CareDx, Inc

Natera, Inc.(NasdaqGS:NTRA) dropped from Russell 1000 Value Index